Key Highlights
- Dr. Joseph Eid appointed Executive Vice President, Research and Development, effective November 11, 2024.
- Over 20 years of experience in medical affairs and drug development in hematology and oncology.
- Former leadership roles at Dragonfly Therapeutics, Luzsana Bio, Merck, and Bristol Myers Squibb.
- RYTELO™ expansion and R&D advancements in hematologic malignancies are priorities under Dr. Eid’s leadership.
- Strategic inducement grant under Nasdaq Rule 5635(c)(4) aligns long-term interests.
Source: Business Wire
Notable Quotes
- “Joe has a deeply impressive track record of more than two decades of global leadership and expertise driving drug development, regulatory, and commercial success for small and large biopharmaceutical companies, including broad experience across hematology and oncology.” – Dr. John A. Scarlett, Chairman and CEO at Geron Corporation
- “I am truly excited to join Geron at this important stage, to build on the Company’s tremendous R&D legacy in hematologic malignancies, and to support the commercial growth of RYTELO by working to expand its reach to appropriate patients in need both in the U.S. and globally.” – Dr. Joseph Eid, EVP, Research and Development at Geron Corporation
SoHC's Take
Dr. Joseph Eid’s appointment represents a significant step for Geron Corporation as it seeks to further establish itself as a leader in hematologic malignancies. With a distinguished career leading medical affairs and clinical development at top-tier biopharmaceutical companies, Dr. Eid brings valuable experience to Geron’s R&D department. His expertise will be crucial as Geron focuses on maximizing the impact of RYTELO™, a first-in-class telomerase inhibitor targeting unmet needs in myelodysplastic syndromes. This appointment, alongside recent leadership additions, reinforces Geron’s commitment to advancing innovative treatments and expanding its footprint in blood cancer therapies.
